Search results for "Antiplatelet drug"

showing 4 items of 4 documents

Secondary Stroke Prevention in Polish Adults: Results from the LIPIDOGRAM2015 Study

2021

Background: The purpose of the study was to evaluate secondary stroke prevention in Poland and its association with sociodemographic factors, place of residence, and concomitant cardiovascular risk factors. Material and methods: From all patients in LIPIDOGRAM2015 Study (n = 13,724), 268 subjects had a history of ischaemic stroke and were included. Results: 165 subjects (61.6%) used at least one preventive medication. Oral antiplatelet and anticoagulation agents were used by 116 (43.3%) and 70 (26.1%) patients, respectively. Only 157 (58.6%) participants used lipid-lowering drugs, and 205 (76.5%) were treated with antihypertensive drugs. Coronary heart disease (CHD) and dyslipidaemia were a…

Oral anticoagulant drugsmedicine.medical_specialtyRMArticleLifestyle modificationOral antiplatelet drugsInternal medicineIschaemic strokemedicineMyocardial infarctioncardiovascular diseasesSecondary stroke preventionStrokePrimary health careoral anticoagulant drugssecondary stroke preventionbusiness.industryRAtrial fibrillationoral antiplatelet drugsGeneral Medicinemedicine.diseaseR1Coronary heart diseaseprimary health careStroke preventionConcomitantMedicinebusiness
researchProduct

Mortality rate and risk factors for gastrointestinal bleeding in elderly patients

2019

Abstract Background Gastrointestinal bleeding (GIB) is burdened by high mortality rate that increases with aging. Elderly patients may be exposed to multiple risk factors for GIB. We aimed at defining the impact of GIB in elderly patients. Methods Since 2008, samples of elderly patients (age ≥ 65 years) with multimorbidity admitted to 101 internal medicine wards across Italy have been prospectively enrolled and followed-up (REPOSI registry). Diagnoses of GIB, length of stay (LOS), mortality rate, and possible risk factors, including drugs, index of comorbidity (Cumulative Illness Rating Scale [CIRS]), polypharmacy, and chronic diseases were assessed. Adjusted multivariate logistic regressio…

RegistrieMaleSettore MED/09 - Medicina Interna030204 cardiovascular system & hematologySeverity of Illness Index0302 clinical medicineRisk Factors80 and over030212 general & internal medicineHospital MortalityProspective StudiesRegistriesProspective cohort studyMultivariate AnalysiAged 80 and overDiverticulosisMortality rateDiverticulosiGastric ulcerAnemiaAnemia; Anticoagulant; Antiplatelet drug; Diverticulosis; Gastric ulcer; Multimorbidity; Internal MedicineItalyPlatelet aggregation inhibitorFemaleGastrointestinal HemorrhageAntiplatelet drugHumanGastrointestinal bleedingmedicine.medical_specialtyLogistic ModelAnemiaSocio-culturaleAnemia Anticoagulant Antiplatelet drug Diverticulosis Gastric ulcer Multimorbidity03 medical and health sciencesInternal medicineSeverity of illnessInternal MedicinemedicineHumansAnemia; Anticoagulant; Antiplatelet drug; Diverticulosis; Gastric ulcer; Multimorbidity; Aged; Aged 80 and over; Female; Gastrointestinal Hemorrhage; Hospital Mortality; Humans; Italy; Length of Stay; Logistic Models; Male; Multivariate Analysis; Platelet Aggregation Inhibitors; Prospective Studies; Registries; Risk Factors; Severity of Illness Index; MultimorbidityAgedPolypharmacybusiness.industryPlatelet Aggregation InhibitorRisk FactorAnemia; Anticoagulant; Antiplatelet drug; Diverticulosis; Gastric ulcer; MultimorbidityAnticoagulantMultimorbidityAnemia Anticoagulant Antiplatelet drug Diverticulosis Gastric ulcer Multimorbidity Aged Aged 80 and over Female Gastrointestinal Hemorrhage Hospital Mortality Humans Italy Length of Stay Logistic Models Male Multivariate Analysis Platelet Aggregation Inhibitors Prospective Studies Registries Risk Factors Severity of Illness Index MultimorbidityLength of Staymedicine.diseaseComorbidityProspective StudieLogistic ModelsMultivariate AnalysisbusinessPlatelet Aggregation Inhibitors
researchProduct

Mediterranean Diet and Physical Activity Decrease the Initiation of Cardiovascular Drug Use in High Cardiovascular Risk Individuals: A Cohort Study

2021

Our aim was to assess whether long-term adherence to a Mediterranean diet (MedDiet) and leisure-time physical activity (LTPA) were associated with a lower initiation of cardiovascular drug use. We studied the association between cumulative average of MedDiet adherence and LTPA and the risk of cardiovascular drug initiation in older adults at high cardiovascular risk (PREvención con DIeta MEDiterránea trial participants) non-medicated at baseline: glucose-lowering drugs (n = 4437), antihypertensives (n = 2145), statins (n = 3977), fibrates (n = 6391), antiplatelets (n = 5760), vitamin K antagonists (n = 6877), antianginal drugs (n = 6837), and cardiac glycosides (n = 6954). One-point increas…

StatinMediterranean dietPhysiologymedicine.drug_classClinical Biochemistryphysical activityFibrateantiplatelet drugs030204 cardiovascular system & hematologyPharmacologyLower riskBiochemistryMetabolic equivalentArticlestatinscardiac glycosides03 medical and health sciences0302 clinical medicineMediterranean cookingMediterranean dietCuina mediterràniamedicine030212 general & internal medicinevitamin K epoxide reductase inhibitorsMolecular BiologyCardiac glycosideglucose-lowering drugsbusiness.industrylcsh:RM1-950mediterranean dietCell BiologyVitamin K antagonistPhysical fitnessCardiovascular agentslcsh:Therapeutics. Pharmacologyantihypertensive drugsantianginal drugsfibratesbusinessCohort studymedicine.drugCondició físicaMedicaments cardiovasculars
researchProduct

Antithrombotic therapies in aortic and peripheral arterial diseases in 2021: a consensus document from the ESC working group on aorta and peripheral …

2021

AbstractThe aim of this collaborative document is to provide an update for clinicians on best antithrombotic strategies in patients with aortic and/or peripheral arterial diseases. Antithrombotic therapy is a pillar of optimal medical treatment for these patients at very high cardiovascular risk. While the number of trials on antithrombotic therapies in patients with aortic or peripheral arterial diseases is substantially smaller than for those with coronary artery disease, recent evidence deserves to be incorporated into clinical practice. In the absence of specific indications for chronic oral anticoagulation due to concomitant cardiovascular disease, a single antiplatelet agent is the ba…

medicine.medical_specialtyConsensusAntiplatelet drugmedicine.drug_classmedicine.medical_treatmentDisease030204 cardiovascular system & hematologyCoronary artery diseasePeripheral Arterial Disease03 medical and health sciences0302 clinical medicinePharmacotherapyFibrinolytic AgentsAntithromboticmedicineHumansIntensive care medicineAortabusiness.industryAnticoagulantAnticoagulantsThrombosismedicine.diseaseThrombosisCardiology and Cardiovascular MedicinebusinessPlatelet Aggregation Inhibitors030217 neurology & neurosurgeryFibrinolytic agentEuropean Heart Journal
researchProduct